CYP19A1 and fatty liver disease: Because ASO therapy targeting ANGPTL3 has been associated with increases in aminotransferases and liver fat17, we also report findings from a repeat-dose cohort evaluating ARO-ANG3 in participants with baseline hepatic steatosis.